These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8336652)

  • 21. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
    Esfandiarpour I; Dabiri SH
    Int J Dermatol; 2007 Aug; 46(8):848-52. PubMed ID: 17651170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative efficacy of the treatment of cutaneous leishmaniasis with monomycin when administered with hemodes and ecmoline].
    Ereshov ME; Khaĭrulin FIa
    Med Parazitol (Mosk); 1987; (4):15-9. PubMed ID: 3119966
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production.
    Castellano LR; Filho DC; Argiro L; Dessein H; Prata A; Dessein A; Rodrigues V
    Hum Immunol; 2009 Jun; 70(6):383-90. PubMed ID: 19480861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
    Oliva G; Foglia Manzillo V; Pagano A
    Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunopathology of American tegumentary leishmaniasis].
    Castés M; Tapia FJ
    Acta Cient Venez; 1998; 49(1):42-56. PubMed ID: 10205916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
    Ridolfi L; Ridolfi R
    Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Monomycin treatment of cutaneous leishmaniasis].
    Timoshenko II
    Voen Med Zh; 1975 Oct; (10):75-6. PubMed ID: 1108421
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A
    Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of cutaneous leishmaniasis of the acute necrotizing type (Borovskiĭ's disease) with monomycin].
    Akovbian AA; Mukhamedov SM
    Vestn Dermatol Venerol; 1968 Jan; 42(1):74-6. PubMed ID: 4906797
    [No Abstract]   [Full Text] [Related]  

  • 34. [The epidemiological efficacy of the chemoprophylaxis of zoonotic cutaneous leishmaniasis in rural inhabitants].
    Shuĭkina EE; Narbadalov MT; Rakhimova NF; Androsov AA
    Med Parazitol (Mosk); 1992; (2):38. PubMed ID: 1435538
    [No Abstract]   [Full Text] [Related]  

  • 35. [The combined therapy of patients with gonorrheal-chlamydial urogenital infections by leukinferon immunocorrection].
    Kuznetsov VP; Dubenskiĭ VV; Delektorskiĭ VV; Igoshin IuM; Beliaev DL; Iashkova GN; Babaiants AA
    Ter Arkh; 1993; 65(11):39-42. PubMed ID: 8108795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate.
    Solomon M; Baum S; Barzilai A; Pavlotsky F; Trau H; Schwartz E
    J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1189-92. PubMed ID: 19298486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cutaneous leishmaniasis in France: towards the end of injectable therapy?].
    Buffet PA; Morizot G
    Bull Soc Pathol Exot; 2003 Jan; 96(5):383-8. PubMed ID: 15015844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Leukinferon immunomodulation in pulmonary tuberculosis].
    Probl Tuberk Bolezn Legk; 2004; (11):47-50. PubMed ID: 15751713
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of cutaneous leishmaniasis with monomycin].
    Kellina OI; Iniakhina AV; Iastrebova RI
    Med Parazitol (Mosk); 1966; 35(3):283-7. PubMed ID: 4888482
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic options for cutaneous leishmaniasis.
    Mahajan VK; Sharma NL
    J Dermatolog Treat; 2007; 18(2):97-104. PubMed ID: 17520466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.